Heart Failure With Reduced Ejection Fraction: Clinical Trials

25 trials for Heart Failure With Reduced Ejection Fraction, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 7 unknown, 5 recruiting, 3 terminated. 25 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 425Completed 7, Unknown 7, Recruiting 5, Terminated 3, Active not recruiting 1, Not yet recruiting 1, Withdrawn 1

Follow Heart Failure With Reduced Ejection Fraction: new trials by email Literature Review of Heart Failure With Reduced Ejection Fraction trials Research Report on Heart Failure With Reduced Ejection Fraction

Trials (filtered) newest first · largest first

All 25 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Mechanistic Clinical Trial Comparing the Pharmacokinetics/Pharmacodynamics of Metoprolol in Heart Failure With Reduced Ejection Fraction Patients With Low vs. High Polygenic Score
Metoprolol Succinate, Beta-Blocker Polygenic Score, Illumina Infinium Global Diversity Array with Enhanced Pharmacogenomics (PGx) - Heart Failure With Reduced Ejection Fraction
Phase 4RecruitingUniversity of Michigan1002026-12-012026-10-15
STEPwise De-escalation and Optimizing Withdrawal of ARNI and SGLT2i in Normalized Heart Failure
Stepwise Withdrawal of ARNI and SGLT2i, Continued Guideline-Directed Medical Therapy - Heart Failure With Reduced Ejection Fraction, Heart Failure
Phase 4RecruitingKyungsub Song802026-08-122026-09-02
Efficacy and Safety of Lactoferrin in Heart Failure Patients
oral Iron, Lactoferrin, lactoferrin and oral iron - Heart Failure With Reduced Ejection Fraction
Phase 4Not yet recruitingCairo University1142024-07-012024-05-24
SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF
Dapagliflozin tablet, Hypertonic Saline Solution, 1 Ml, Furosemide Injection - Heart Failure Acute, Diabetes Type 2
Phase 4UnknownUniversity of Palermo5442024-06-012024-06-06
Colchicine in Acutely Decompensated HFREF
Colchicine 0.6 mg, Control/Placebo group - Heart Failure, Decompensated Heart Failure
Phase 4RecruitingUniversity of Virginia302024-06-012024-05-08
Empagliflozin in Heart Failure With Reduced Ejection Fraction and End Stage Renal Disease
Empagliflozin 25 MG, Placebo - Heart Failure With Reduced Ejection Fraction, End Stage Renal Disease on Dialysis
Phase 4RecruitingNational Taiwan University Hospital952024-03-132026-10-28
Determination of Drug Levels for Pharmacotherapy of Heart Failure
Nebivolol, Valsartan and Sacubitril, Carvedilol - Cardiovascular Diseases, Heart Failure With Reduced Ejection Fraction
Phase 4UnknownUniversity Hospital Ostrava1002024-03-012024-01-18
Initiation of ARNi and SGLT2i in Patients With HFrEF
Sacubitril-valsartan, SGLT2 inhibitor - Heart Failure With Reduced Ejection Fraction
Phase 4CompletedUniversidade do Porto622023-08-042025-11-19
The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF)
Ferric derisomaltose, Placebo - Heart Failure With Reduced Ejection Fraction, Iron Deficiency
Phase 4RecruitingChina-Japan Friendship Hospital1462023-08-012026-11-06
SGLT2 Inhibitors and Treatment of Heart Failure in Severe Renal Insufficiency
SGLT-2 inhibitor - Heart Failure With Reduced Ejection Fraction, Renal Insufficiency, Chronic
Phase 4TerminatedPeking University People's Hospital112023-03-092024-04-30
Screening for Advanced Heart Failure IN Stable outPatientS - The SAINTS Study (SAINTS B)
CardioMEMS HF System, Standard heart failure medical therapy - Advanced Heart Failure, Heart Failure With Reduced Ejection Fraction
Phase 4UnknownFinn Gustafsson602023-03-022023-03-20
ERTU-SODIUM: Study on the Effects of Ertugliflozin on Sodium Storage, Interstitial Volume, and Plasma Volume in HFrEF
Ertugliflozin, Placebo - Heart Failure With Reduced Ejection Fraction, Congestion
Phase 4CompletedIcahn School of Medicine at Mount Sinai282023-02-022026-05-11
Effect of Empagliflozin on NT-Pro Brain Natriuretic Peptide in Heart Failure Patients With Reduced Ejection Fraction
Empagliflozin 10 MG - Heart Failure With Reduced Ejection Fraction
Phase 4UnknownAlexandria University602022-12-152023-03-21
Telemonitored Fast Track Medical Sequencing for Heart Failure With Reduced Ejection Fraction
GDMT - Heart Failure With Reduced Ejection Fraction
Phase 4Active not recruitingGöteborg University602022-10-222025-04-15
HF Patients With LVADs Being Treated With SGLT2i
SGLT2i, No SGLT2i - Heart Failure With Reduced Ejection Fraction
Phase 4CompletedUniversity of Chicago322022-09-082026-06-03
Levosimendan In Ambulatory Heart Failure Patients
Levosimendan, Placebo - Heart Failure New York Heart Association Class III, Heart Failure New York Heart Association Class IV
Phase 4TerminatedMedical University of Bialystok702021-12-152025-05-09
Benefits of Empagliflozin in Patients With Heart Failure and Reduced Ejection Fraction Without Diabetes Mellitus
Empagliflozin 10 mg, Placebo - Heart Failure With Reduced Ejection Fraction
Phase 4CompletedAshraf Wasfy Beshay Aziz742021-07-262024-10-09
Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone
Sodium zirconium cyclosilicate, Placebo, Spironolactone - Hyperkalaemia, Heart Failure With Reduced Ejection Fraction
Phase 4CompletedAstraZeneca3662021-03-082025-07-09
The Effects of SGLTi on Diabetic Cardiomyopathy
Dapagliflozin - Type2 Diabetes, Heart Failure With Reduced Ejection Fraction
Phase 4UnknownThe University of Hong Kong302020-04-092021-08-03
Comparison of Effects of Atorvastatin Versus Rosuvastatin on Cardiac Function in Heart Failure Patients
Atorvastatin Oral Tablet, Rosuvastatin Oral Tablet - Heart Failure With Reduced Ejection Fraction
Phase 4UnknownPost Graduate Institute of Medical Education and Research, Chandigarh802019-10-162021-10-19

Showing 20 of 25. Sign in to see all of them.

Narrower conditions

Heart Failure (6)  ·  Cardiovascular Diseases (2)  ·  Iron Deficiencies (2)  ·  Diabetes Mellitus, Type 2 (1)  ·  Genetic Risk Score (1)  ·  Heart Failure, Systolic (1)  ·  Heart Valve Diseases (1)  ·  Hyperkalemia (1)  ·  Kidney Failure, Chronic (1)  ·  Renal Insufficiency, Chronic (1)  ·  Ventricular Dysfunction, Left (1)

Broader conditions

Heart Diseases (7)  ·  Cardiovascular Diseases (6)  ·  Metabolic Diseases (4)  ·  Nutritional and Metabolic Diseases (4)  ·  Disease Attributes (3)  ·  Pathologic Processes (3)  ·  Pathological Conditions, Signs and Symptoms (3)  ·  Chronic Disease (2)  ·  Female Urogenital Diseases (2)  ·  Female Urogenital Diseases and Pregnancy Complications (2)  ·  Iron Metabolism Disorders (2)  ·  Kidney Diseases (2)  ·  Male Urogenital Diseases (2)  ·  Renal Insufficiency (2)  ·  Urogenital Diseases (2)

Interventions

sacubitril and valsartan sodium hydrate drug combination (4)  ·  Sodium-Glucose Transporter 2 Inhibitors (3)  ·  empagliflozin (3)  ·  Iron (2)  ·  Metoprolol (2)  ·  Spironolactone (2)  ·  dapagliflozin (2)  ·  Atorvastatin (1)  ·  Bisoprolol (1)  ·  Carvedilol (1)  ·  Chlorothiazide (1)  ·  Colchicine (1)  ·  Diastole (1)  ·  Echocardiography (1)  ·  Enalapril (1)

Sponsors

University of Virginia (2)  ·  Alexandria University (1)  ·  Ashraf Wasfy Beshay Aziz (1)  ·  AstraZeneca (1)  ·  Brigham and Women's Hospital (1)  ·  Cairo University (1)  ·  China-Japan Friendship Hospital (1)  ·  Finn Gustafsson (1)  ·  Fundación para la Investigación del Hospital Clínico de Valencia (1)  ·  Göteborg University (1)  ·  Icahn School of Medicine at Mount Sinai (1)  ·  Kyungsub Song (1)  ·  Medical University of Bialystok (1)  ·  National Taiwan University Hospital (1)  ·  Novartis Pharmaceuticals (1)

Countries

United States (6)  ·  Czechia (3)  ·  Poland (3)  ·  Spain (3)  ·  Canada (2)  ·  China (2)  ·  Egypt (2)  ·  Portugal (2)  ·  South Korea (2)  ·  Sweden (2)  ·  United Kingdom (2)  ·  Argentina (1)  ·  Belgium (1)  ·  Brazil (1)  ·  Denmark (1)

Top investigators

Antonio Abbate, MD (1)  ·  Ashish K Kakkar (1)  ·  Carlos G Santos-Gallego, MD (1)  ·  Chih-Cheng Wu, MD. PhD (1)  ·  Donna Shu-Han Lin, MD (1)  ·  Finn Gustafsson, MD, professor, PhD, DMSci (1)  ·  Giuseppe Miceli, PhD (1)  ·  Hesham B Mahmoud, Professor of Cardiology (1)  ·  Hyung Gon Je, Professor (1)  ·  Jacek Kubica, Prof. MD (1)  ·  Jadwiga Nessler, Prof. MD (1)

Results publications

PMID 15963399, PMID 20607462, PMID 21440872, PMID 21885793, PMID 22980301, PMID 26240596, PMID 29239515, PMID 29433525, PMID 31134724, PMID 31820537, PMID 32139695, PMID 32709292, PMID 32800508, PMID 32970396, PMID 34447992, PMID 35066737, PMID 35241246, PMID 35604416, PMID 36607775, PMID 37391470, PMID 37676213, PMID 37678704, PMID 38878009, PMID 39566872, PMID 40855136

NIH funding

2015 (1), 2018 (1), R01HL178410 (1)